Updated Jul 16, 2026
Townsend Richard Nolan has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $714K.
Richard Nolan Townsend is the Chief Executive Officer of Lexeo Therapeutics, Inc., a clinical-stage genetic medicines company. He has been involved in multiple SEC filings related to the company's operations.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale | 25.9K | $4.48 | $116K |
| 2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | A — Grant or award | 67.0K | $0.00 | |
| 2026-05-20 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale | 3.3K | $5.06 | $17K |
| 2026-04-07 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale [10b5-1] | 55.0K | $5.69 | $313K |
| 2026-03-18 | LXEO | Lexeo Therapeutics, Inc. | A — Grant or award | 2.6K | $2.64 | $7K |
| 2026-02-20 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale | 10.2K | $6.38 | $65K |
| 2026-02-06 | LXEO | Lexeo Therapeutics, Inc. | A — Grant or award | 161.7K | $0.00 | |
| 2025-10-15 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale | 148 | $9.56 | $1K |
| 2025-10-15 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale | 13.0K | $8.94 | $116K |
| 2025-10-15 | LXEO | Lexeo Therapeutics, Inc. | A — Grant or award | 33.0K | $0.00 | |
| 2025-09-12 | LXEO | Lexeo Therapeutics, Inc. | A — Grant or award | 2.2K | $2.64 | $6K |
| 2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale | 1.1K | $4.67 | $5K |
| 2024-12-12 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.5K | $8.20 | $20K |
| 2024-12-12 | LXEO | Lexeo Therapeutics, Inc. | M — Option exercise [10b5-1] | 2.5K | $2.33 | $6K |
| 2024-11-13 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.5K | $7.82 | $20K |
| 2024-11-13 | LXEO | Lexeo Therapeutics, Inc. | M — Option exercise [10b5-1] | 2.5K | $2.33 | $6K |
| 2024-10-15 | LXEO | Lexeo Therapeutics, Inc. | S — Open-market sale [10b5-1] | 5.0K | $8.10 | $40K |
| 2024-10-15 | LXEO | Lexeo Therapeutics, Inc. | M — Option exercise [10b5-1] | 5.0K | $2.33 | $12K |
Richard Nolan Townsend is the Chief Executive Officer of Lexeo Therapeutics, Inc., a clinical-stage genetic medicines company. He has been involved in multiple SEC filings related to the company's operations.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 10 open-market sales ($714K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Townsend Richard Nolan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.